Appadurai Vivek, DeBarber Andrea, Chiang Pei-Wen, Patel Shailendra B, Steiner Robert D, Tyler Charles, Bonnen Penelope E
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
Physiology & Pharmacology Department, Oregon Health & Science University, Portland, OR 97239, USA.
Mol Genet Metab. 2015 Dec;116(4):298-304. doi: 10.1016/j.ymgme.2015.10.010. Epub 2015 Oct 26.
Cerebrotendinous Xanthomatosis (CTX) is a treatable inborn error of metabolism caused by recessive variants in CYP27A1. Clinical presentation varies, but typically includes infant-onset chronic diarrhea, juvenile-onset bilateral cataracts, and later-onset tendinous xanthomas and progressive neurological dysfunction. CYP27A1 plays an essential role in side-chain oxidation of cholesterol necessary for the synthesis of the bile acid, chenodeoxycholic acid, and perturbations in this gene that reduce enzyme activity result in elevations of cholestanol. It is commonly held that CTX is exceedingly rare, but epidemiological studies are lacking. In order to provide an accurate incidence estimate of CTX, we studied the ExAC cohort of ~60,000 unrelated adults from global populations to determine the allele frequency of the 57 variants in CYP27A1 reported pathogenic for CTX. In addition, we conducted bioinformatics analyses on these CTX-causing variants and determined a bioinformatics profile to predict variants that may be pathogenic but have not yet been reported in the CTX patient literature. An additional 29 variants were identified that met bioinformatics criteria for being potentially pathogenic. Incidence was estimated based allele frequencies of pathogenic CTX variants plus those determined to be potentially pathogenic. One variant, p.P384L, previously reported in three unrelated CTX families had an allele frequency ≥ 1% in European, Latino and Asian populations. Three additional mutations had a frequency of ≥ 0.1% in Asian populations. CTX disease incidence was calculated excluding the high frequency p.P384L and separately using a genetic paradigm where this high frequency variant only causes classic CTX when paired in trans with a null variant. These calculations place CTX incidence ranging from 1:134,970 to 1:461,358 in Europeans, 1:263,222 to 1:468,624 in Africans, 1:71,677 to 1:148,914 in Americans, 1:64,267 to 1:64,712 in East Asians and 1:36,072 to 1:75,601 in South Asians. This work indicates CTX is under-diagnosed and improved patient screening is needed as early intervention prevents disease progression.
脑腱黄瘤病(CTX)是一种由CYP27A1基因隐性变异引起的可治疗的先天性代谢缺陷病。临床表现各异,但通常包括婴儿期起病的慢性腹泻、青少年期起病的双侧白内障,以及后期出现的腱黄瘤和进行性神经功能障碍。CYP27A1在胆固醇侧链氧化中起关键作用,而胆固醇侧链氧化是合成胆汁酸鹅去氧胆酸所必需的,该基因的扰动会降低酶活性,导致胆甾烷醇升高。人们普遍认为CTX极为罕见,但缺乏流行病学研究。为了准确估计CTX的发病率,我们研究了来自全球人群的约60000名无关成年人的ExAC队列,以确定CYP27A1中57个已报道的对CTX致病的变异的等位基因频率。此外,我们对这些导致CTX的变异进行了生物信息学分析,并确定了一个生物信息学图谱,以预测可能致病但尚未在CTX患者文献中报道的变异。另外还鉴定出29个符合潜在致病性生物信息学标准的变异。根据致病CTX变异以及被确定为潜在致病变异的等位基因频率来估计发病率。一个名为p.P384L的变异,先前在三个无关的CTX家族中被报道,在欧洲、拉丁裔和亚洲人群中的等位基因频率≥1%。另外三个突变在亚洲人群中的频率≥0.1%。计算CTX疾病发病率时,排除了高频的p.P384L,并分别使用一种遗传模式,即这种高频变异只有在与无效变异反式配对时才会导致典型的CTX。这些计算得出,欧洲人的CTX发病率在1:134970至1:461358之间,非洲人在1:263222至1:468624之间,美洲人在1:71677至1:148914之间,东亚人在1:64267至1:64712之间,南亚人在1:36072至1:75601之间。这项研究表明CTX诊断不足,需要改进患者筛查,因为早期干预可防止疾病进展。